Obesity and Weight Loss

Obesity is a complex chronic disease affecting over 650 million adults worldwide, with rates having nearly tripled since 1975. It's defined as excessive body fat accumulation that presents health risks, typically measured using body mass index (BMI) where 30 or above indicates obesity. Far from being simply about willpower or eating too much, obesity results from intricate interactions between genetics, biology, environment, psychology, and social factors. The body tightly regulates weight through hormones and neural circuits in the brain that control hunger, fullness, metabolism, and fat storage. Dozens of hormones including leptin (produced by fat cells), ghrelin (the "hunger hormone"), GLP-1, and others communicate between the digestive system, fat tissue, and brain to regulate appetite and energy expenditure. In people with obesity, these regulatory systems often become dysregulated—the brain may not properly respond to satiety signals, metabolism may slow to defend a higher weight, and hunger hormones can remain elevated. Genetics plays a substantial role, with hundreds of gene variants influencing weight, and certain rare genetic conditions cause severe obesity. Environmental factors including the modern food environment with highly processed, calorie-dense foods, sedentary lifestyles, stress, inadequate sleep, certain medications, and socioeconomic factors all contribute. Obesity increases risk for type 2 diabetes, heart disease, stroke, certain cancers, sleep apnea, osteoarthritis, liver disease, and mental health conditions.

Treatment approaches span lifestyle modification, medication, and surgery. Behavioral interventions combining reduced calorie intake, increased physical activity, and behavioral strategies form the foundation, though sustaining weight loss long-term through lifestyle alone is challenging for most people due to biological adaptations that defend against weight loss. Medical nutrition therapy with dietitians, structured programs, and cognitive behavioral therapy provide additional support. Several medications are now available that work through different mechanisms. Phentermine-topiramate combines appetite suppression with metabolic effects. Naltrexone-bupropion acts on brain reward pathways. Orlistat blocks fat absorption in the intestines. The most significant recent advance has been GLP-1 receptor agonists, drugs originally developed for diabetes that also cause substantial weight loss by mimicking a gut hormone that increases feelings of fullness and reduces appetite—these include liraglutide (approved for weight management) and semaglutide, with once-weekly injections producing average weight loss of 10-15% of body weight. Tirzepatide, which activates both GLP-1 and GIP receptors, has shown even greater effects with average weight loss around 15-20%. Bariatric surgery including sleeve gastrectomy and gastric bypass remains the most effective treatment for severe obesity, producing substantial sustained weight loss and often resolving diabetes and other conditions. The procedures work through multiple mechanisms beyond stomach size reduction, including hormonal changes affecting appetite and metabolism. Increasingly, obesity is being recognized and treated as a chronic disease requiring ongoing management rather than a temporary condition to be cured.

Response to both medications and lifestyle interventions varies dramatically between individuals—some people achieve substantial weight loss while others respond minimally, and predicting who will benefit from which treatment remains imperfect. Most people who lose weight through lifestyle changes regain much or all of it within a few years as biological systems actively work to restore the previous weight set point, making maintenance extraordinarily difficult without ongoing treatment. Current GLP-1 medications, while effective, require ongoing injections and cause gastrointestinal side effects including nausea, vomiting, and diarrhea that lead some people to discontinue treatment. Cost and access represent major barriers—newer medications are expensive, often not covered by insurance, and unavailable in many countries. Weight stigma and the widespread misconception that obesity reflects personal failure rather than a medical condition create barriers to seeking and receiving appropriate treatment. Bariatric surgery, while effective, carries surgical risks, requires lifelong dietary modifications, and isn't appropriate or available for everyone. Some people experience weight regain even after surgery. The healthcare system often lacks adequate time and resources for comprehensive obesity treatment, with limited availability of behavioral support programs. Certain populations including children and adolescents, people with psychiatric conditions, and those with history of eating disorders need specialized approaches that aren't well-established. Better ways to prevent obesity and identify at-risk individuals before significant weight gain occurs would address the problem upstream rather than treating established disease.

Multiple next-generation weight loss medications are in Phase 2 and Phase 3 trials, many building on the GLP-1 mechanism. Retatrutide, a triple agonist activating GLP-1, GIP, and glucagon receptors, produced average weight loss exceeding 24% in Phase 2 trials and is advancing to larger studies. Orforglipron, an oral GLP-1 agonist eliminating the need for injections, showed substantial weight loss in mid-stage trials and could improve convenience and adherence. CagriSema combines semaglutide with cagrilintide (an amylin analogue) and demonstrated superior weight loss compared to semaglutide alone. Survodutide, a dual GLP-1/glucagon receptor agonist, is in advanced trials. Multiple pharmaceutical companies are developing various combinations and novel receptor agonists aiming to exceed the weight loss achieved by current drugs while improving tolerability. Bimagrumab, an antibody blocking myostatin (a protein that limits muscle growth), is being tested to preserve or increase muscle mass during weight loss, addressing the common problem of losing lean tissue along with fat. Setmelanotide, which activates melanocortin-4 receptors in the brain regulating appetite, is approved for rare genetic obesity disorders and being studied in other forms of obesity. New bariatric surgical techniques and endoscopic procedures that don't require surgery—including devices that coat the intestine or create barriers affecting nutrient absorption—are in advanced testing as less invasive alternatives. Closed-loop systems combining continuous glucose monitors with automated insulin and/or GLP-1 delivery are being developed.

Gene therapy approaches delivering instructions to modify metabolism, increase energy expenditure, or alter appetite regulation through one-time treatments are in early development. CRISPR gene editing is being explored to modify genes affecting weight, though technical and ethical considerations require careful evaluation. Scientists are developing personalized medicine approaches using genetics, gut microbiome analysis, metabolomics, and artificial intelligence to predict which treatments will work best for individual patients before starting therapy. Researchers are investigating the gut-brain axis extensively, studying how intestinal bacteria influence weight regulation, appetite, metabolism, and response to interventions—fecal microbiota transplants from lean donors and targeted probiotics are being explored as potential treatments. Brown adipose tissue (brown fat), which burns calories to generate heat rather than storing them, is a research focus with scientists investigating drugs that could activate existing brown fat or convert white fat to brown fat. Researchers are developing vaccines targeting hormones involved in appetite regulation as potential long-lasting alternatives to repeated injections. Nanotechnology-based drug delivery systems that could release weight loss medications in response to specific metabolic signals are in development. Scientists are studying the mechanisms behind bariatric surgery's metabolic effects to develop drugs or less invasive procedures that replicate these benefits without surgery. Appetite-regulating neurons in specific brain regions are being mapped in detail, with optogenetic and chemogenetic approaches (using light or designer drugs to precisely control these neurons) being explored. Artificial intelligence is analyzing vast datasets to identify new drug targets, predict obesity risk years before weight gain, and discover existing drugs that might be repurposed for weight management. Researchers are investigating whether targeting cellular aging processes including senescent cells could address metabolic dysfunction associated with obesity. Bioelectronic medicine approaches using targeted nerve stimulation to affect appetite, satiety, or metabolism are being explored as non-pharmaceutical alternatives.